Facebook
Twitter
LinkedIn
ForwardCardiovascular Conference Series: Beyond Statins: Therapies to Decrease Cardiovascular Risk
PCSK9 is an established target for cholesterol-lowering therapies. Further study of PCSK9 regulatory mechanisms may identify additional control points for pharmacological inhibition of PCSK9-mediated LDLR degradation. PCSK9 function could reflect ancient roles in the fasting-feeding cycle and in linking lipoprotein metabolism with innate immunity. Dr. McCullough will discuss the regulatory function of PSK9, as well as results from recent clinical trials on the efficacy and safety of PSK9.
Locations
| Live Event - Baptist Hospital - 5MCVI |
| Videoconference to South Miami Hospital - MCVI Conference Room |
| Videoconference to Homestead Hospital - Pineapple Room |
| Videoconference to Mariners Hospital - Educational Room |
| Webcast |
Target Audience
Cardiologists, Interventional Cardiologists, Interventional Radiologists, General Internists,Primary Care Physicians, Internists, Pulmonologists, General Surgeons, Orthopedic Surgeons, Urologists, Gynecologists, Anesthesiologists, Emergency Medicine Physicians, Hospitalists, Nurses, Pharmacists, Respiratory Therapists and other interested healthcare providers.
Learning Objectives
- Review global cardiovascular risk.
- Demonstrate the regulatory function of PCSK9.
- Synthesize the results of randomized trials with respect to efficacy and safety of PCSK9.
Peter A. McCullough, M.D., MPH, FACP, FACC, FCCP, FAHA, FNKF, FNLA, FCRSA
Vice Chief of Medicine
Baylor University Medical Center
Dallas, Texas
Principal Faculty in Internal Medicine
Texas A & M University Health Sciences Center
Dallas, Texas
Peter A. McCullough, M.D., indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation or discussion.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-103402, by the Florida Boards of Medicine and Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurses, Nurse Practitioners, Pharmacists and Respiratory Care (direct delivery). Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Pharmacy
- 1.00 Florida Board of Respiratory Therapy
Pre-registration is required. Please log in to register.
Required Hardware/Software
Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.